Press Releases

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination…

Debiopharm to unveil new pre-clinical and clinical research advances in DDR inhibition, dual payload ADCs, and AI-driven biomarkers at AACR…

GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug

StudentsPool fait rayonner l’innovation patients en remportant le 10ᵉ Challenge Qualité de vie du patient et reçoit le prix de…

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment

Swiss-Based Debiopharm Seeks To Boost Innovation In Japanese Cancer Research Through The New “Ideal Japan” Program

Debiopharm Takes a Step Forward for Children with CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever…

Debiopharm Forges AI-Powered Alliance with NetTargets to Pioneer Dual-Payload ADCs Against Drug-Resistant Cancers

Debiopharm Leverages Risklick’s AI-Powered Solution to Improve Protocol Development Efficiency